Cost-effectiveness of a stepped care intervention to prevent depression and anxiety in late life: randomised trial

Background There is an urgent need for the development of cost-effective preventive strategies to reduce the onset of mental disorders. Aims To establish the cost-effectiveness of a stepped care preventive intervention for depression and anxiety disorders in older people at high risk of these conditions, compared with routine primary care. Method An economic evaluation was conducted alongside a pragmatic randomised controlled trial (ISRCTN26474556). Consenting individuals presenting with subthreshold levels of depressive or anxiety symptoms were randomly assigned to a preventive stepped care programme (n = 86) or to routine primary care (n = 84). Results The intervention was successful in halving the incidence rate of depression and anxiety at €563 (£412) per recipient and €4367 (£3196) per disorder-free year gained, compared with routine primary care. The latter would represent good value for money if the willingness to pay for a disorder-free year is at least €5000. Conclusions The prevention programme generated depression- and anxiety-free survival years in the older population at affordable cost.

[1]  P. Cuijpers,et al.  Stepped-care prevention of anxiety and depression in late life: a randomized controlled trial. , 2009, Archives of general psychiatry.

[2]  Filip Smit,et al.  Preventing the onset of depressive disorders: a meta-analytic review of psychological interventions. , 2008, The American journal of psychiatry.

[3]  P. Cuijpers,et al.  Costs of nine common mental disorders: implications for curative and preventive psychiatry. , 2006, The journal of mental health policy and economics.

[4]  P. Cuijpers,et al.  Cost-effectiveness of preventing depression in primary care patients: Randomised trial , 2007 .

[5]  P. Cuijpers,et al.  Minimal-contact psychotherapy for sub-threshold depression in primary care , 2004, British Journal of Psychiatry.

[6]  A. Beekman,et al.  Patients' preferences in the treatment of depressive disorder in primary care. , 2004, General hospital psychiatry.

[7]  S. Byford,et al.  Acceptable mental health care? A new decision-making tool for cost-effectiveness analysis - Mental Health Research Review 9 , 2003 .

[8]  A. Beekman,et al.  The impact of depression on the well‐being, disability and use of services in older adults: a longitudinal perspective , 2002, Acta psychiatrica Scandinavica.

[9]  W. Katon,et al.  Cost-effectiveness of a collaborative care program for primary care patients with persistent depression. , 2001, The American journal of psychiatry.

[10]  A. V. van Balkom,et al.  Consequences of anxiety in older persons: its effect on disability, well-being and use of health services , 1999, Psychological Medicine.

[11]  N. Pelosi Reducing risks of mental disorders. , 1996, American Psychologist.

[12]  George W. Torrance,et al.  Canadian Guidelines for Economic Evaluation of Pharmaceuticals , 1996, PharmacoEconomics.

[13]  P. Langley The November 1995 Revised Australian Guidelines for the Economic Evaluation of Pharmaceuticals , 1996, PharmacoEconomics.

[14]  M J Al,et al.  Costs, effects and C/E-ratios alongside a clinical trial. , 1994, Health economics.

[15]  L. Roijen,et al.  Manual Trimbos/iMTA Questionnaire for Costs Associated with Psychiatric Illness , 2002 .

[16]  M C Weinstein,et al.  Guidelines for pharmacoeconomic studies. Recommendations from the panel on cost effectiveness in health and medicine. Panel on cost Effectiveness in Health and Medicine. , 1997, PharmacoEconomics.

[17]  A. Detsky,et al.  Canadian guidelines for economic evaluation of pharmaceuticals. Canadian Collaborative Workshop for Pharmacoeconomics. , 1996, PharmacoEconomics.